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Diabetes, one of the most commonly seen metabolic disorders, is aﬀecting a major area of population in many developing as
well as most of the developed countries and is becoming an alarming concern for the rising cost of the healthcare system. Latent
Autoimmune Diabetes in Adults (LADA) is a form of diabetes which is less recognized and underdiagnosed type of diabetes which
appears to have characteristics of both type 1 (autoimmune in nature) and type 2 diabetes (adult age at onset and initial response
to oral hypoglycemic agents). An epidemiological study was carried out on 500 patients in the western region of India. Various
parameters such as age at onset, duration of diabetes, gender, basal metabolic index (BMI), type of diabetes, family history, HbA1c
levels, cholesterol levels, and current treatment regimen were evaluated and correlated with type 1 and type 2 diabetes. Moreover,
diagnostic markers for LADA, namely, GAD autoantibodies and C-peptide levels, were determined for 80 patients selected from
the epidemiological study. Some of the results obtained were found to be consistent with the literature whereas some results were
found to be contradictory to the existing data.
1.Introduction
Diabetes mellitus (DM) includes a group of carbohydrate
metabolism disorders which is characterized by hyper-
glycemiaandleadstolong-termmacrovascularandmicrova-
scular complications. The prevalence of diabetes mellitus is
increasing signiﬁcantly in most of the developed and many
developing countries, and it is of great concern [1, 2]. The
worldwide prevalence of diabetes mellitus has risen dram-
atically over the past two decades. It is one of the most
common chronic endocrine disorders aﬀecting millions of
people worldwide. The International Diabetes Federation
(IDF) data indicates that by the year 2025, the number of
people aﬀected by diabetes will reach 333 million. Although
all forms of diabetes are characterized by hyperglycemia,
the pathogenic mechanisms by which hyperglycemia arises
diﬀer widely. American Diabetes Association categorized
DM mainly as types 1 and 2d i a b e t e sand the others [3].
Individuals with type 1 diabetes show extensive beta-cell
destruction, and therefore no residual insulin secretion,
requiring insulin for survival. Autoimmune β-cell destruc-
tion is the main cause of insulin deﬁciency in type 1 diabetes
[4]. In some individuals with diabetes, adequate glycaemic
control can be achieved with weight reduction, exercise,
and/or oral agents. These individuals, that is, patients
of type 2 diabetes, therefore, do not require insulin and
may even revert to impaired glucose tolerance (IGT) or
normoglycaemia [5]. It is mainly a heterogeneous disease
with a complex pattern of inheritance. Type 2 diabetes is the
commonest form of diabetes constituting about 90% of the
total diabetic population, whereas type 1 diabetes constitutes
about 10–15% of the diabetic population. Geographic,
environmental, and genetic factors all play a major role in
the variation of incidence of all types of diabetes. Although
diabetes is classiﬁed into two major types—type 1 (insulin
dependent) and type 2 (insulin independent) diabetes, there2 ISRN Pharmacology
are some forms of diabetes which cannot be classiﬁed into
either of these categories. One such less recognized and
underdiagnosedmanifestationofDMappearstoaﬀectadults
with many characteristics of type 2 diabetes and carries a
high risk of insulin dependency progression, the condition
known as Latent Autoimmune Diabetes in Adults (LADA)
[3].TheusualfeaturesofLADApatientsreported areonsetof
diabetes at ≥25 years of age, clinical presentation masquerad-
ingasnonobesetype2diabetes,unlikelytohaveafamilyhistory
oftype2diabetes,initialcontrolofhyperglycemiawithdietand
oral antidiabetic agents, evolution to insulin necessity within
months, and some features of type 1 diabetes such as low fasting
C-peptide and positive GAD auto antibodies [6–8]. About
20% of the patients diagnosed with type 2 diabetes may have
LADA. This accounts for 5–10% of the total diabetes popu-
lation, the same number as type 1 diabetes [9]. Despite the
frequency of LADA, there are no universal recommendations
regarding testing for islet antibodies in adult onset diabetes.
A reliable clinical strategy is required to identify which adults
with diabetes have a high likelihood of LADA and need
testing for islet antibodies. Another important characteristic
of LADA which faces controversy is the family history. Some
reports suggest that LADA patients are unlikely to have fam-
ily history of type 2 diabetes [10] while a recent study (Nord-
Trøndelag Health Study) indicated strong evidence of family
history as an important risk factor for LADA [11]. India is
witnessing an epidemic of diabetes, more speciﬁcally type 2
diabetes. It has been observed that the onset of type 2 diabetes
occurs at an early age in Asian population. Very less work
has been done in context to LADA in the Indian population.
Since it has been observed that the prevalence of diabetes
in India and especially in Gujarat or Western population is
signiﬁcantly high, it follows that the prevalence of LADA in
this population can be predicted to be high. Also, from the
above reports, it is obvious that the diﬀerences between type
1d i a b e t e sand LADA are not very well understood. Similarly,
due to certain characteristics of LADA which phenotypically
resemble type 2 diabetes, many LADA patients are often
initially misdiagnosed as type 2 diabetic patients. Since not
much work has been done in the ﬁeld of LADA in India,
wherediabetes aﬀectsa signiﬁcantsectorof the society, study
of prevalence, characteristics and immunological markers of
LADA,especiallyintheWestern(Gujarat)population,where
the prevalence of diabetes is high, would help in providing
valuable insights into the underlying molecular and genetic
mechanisms, similarities or diﬀerences with other types of
diabetes and designing appropriate diagnostic criteria and
treatment regimen for such patients.
2. Methods
2.1. Epidemiological Study. The epidemiological study was
carried out on 500 patients randomly selected, having any
type of diabetes (excluding prediabetic syndrome or IGT) as
per the Study Protocol approved by the Independent Ethics
Committee Medilink Research Centre, Medilink Hospital,
Ahmedabad, India.
2.1.1. Patient Recruitment and Screening. Patients attend-
ing DIACARE Clinic (Ahmedabad) and Medilink Hospital
(Ahmedabad) conﬁrmed as diabetic as per WHO criteria
[12] were included in the epidemiological study. Patients not
having diabetes or who are seriously ill were excluded from
the study. All patients were given a patient information sheet
and an informed consent form. Blood (10mL) was collected
for determination of various biochemical parameters.
2.1.2. Study Procedure. Various parameters evaluated for the
epidemiological study were present age; age at onset of dia-
betes; duration of diabetes; gender; basal metabolic index
(BMI); type of diabetes; family history of diabetes, if any;
diet and lifestyle; medical complications; cholesterol levels;
HbA1c levels; the current treatment regimen that the patient
was following.
2.2. Estimation of C-Peptide Levels (β-Cell Function) and
GAD Autoantibodies
2.2.1. Patient Recruitment. Eighty diabetic patients from
the epidemiological study, attending DIACARE Clinic, and
Medilink Hospital, Ahmedabad, were selected and recruited
after checking the required inclusion and exclusion criteria.
These patients were grouped into the four categories accord-
ing to their type of diabetes: type-1 diabetes (n = 20); type 2
diabetes (n = 20); LADA suspects (n = 20); and patients
newly diagnosed with diabetes and who could not been as-
signed a particular class of diabetes (n = 20).
Patients who were seriously ill or who had any speciﬁc
objection for undergoing the tests for estimation of C-pep-
tide and GAD auto antibodies were excluded from the study.
2.2.2. Determination of C-Peptide Levels. C-peptide levels
were determined in the above groups using the EiAsy Way
diagnostic kit (Diagnostic Biochem Canada Inc., Canada).
The kit was used for the indirect quantitative determination
of C-peptide by Enzyme Linked Immunosorbant Assay
(ELISA) in human serum in vitro [13].
2.2.3. Estimation of GAD Autoantibodies. GAD autoantibod-
ies were determined in the above-mentioned groups using
Isletest GAD diagnostic kit (Biomerica, USA). The kit was
used for an in vitro qualitative ELISA test for detection of
circulating autoantibodies against GAD antigens [14].
2.3. Statistical Analysis. After recording the details of pa-
tients, the data was sorted into diﬀerent groups according to
thetypeofdiabetes (type1,type2, LADA,andundiagnosed).
The mean values were calculated for each parameter and
compared in diﬀerent groups. All results were expressed as
mean ± SEM or as percentage. The statistical diﬀerences be-
tween various groups were evaluated by One Way Analysis of
Variance (ANOVA) followed by Tukey’s Test or Chi-Square
Test with Yate’s Correction (for nonparametric data). Data
were considered signiﬁcant at P<0.05 and highly signiﬁ-
cant at P<0.001. Statistical analysis was performed using
GraphPad statistical software.ISRN Pharmacology 3
Table 1: Comparative evaluation of diﬀerent parameters in diﬀerent types of diabetes including LADA.
Parameter Type 1 Type 2 LADA Undiagnosed
Prevalence (%) 6.2 79.2 5 9.6
Gender-wise prevalence
Males (%) 38.7 62.12 80 54.16
Females (%) 61.3 37.87 20 45.83
Average age (yrs) 21.64 ±1.97 55.69 ±0.47 40.8 ±1.48 44.46 ±1.56
Range (yrs) 6–59 33–82 23–55 25–65
Mean age at onset of diabetes (yrs) 12.55 ± 1.34 48.01 ± 0.53 3 .4 ±2.15 37.68 ± 1.28
Range (yrs) 2–30 30–75 22–44 20–45
Prevalence in diﬀerent age groups (%) M F M F M F M F
<12 years 16.66 10.52 0 0 0 0 0 0
12–24 years 41.66 63.15 0 0 5 0 0 0
25–35 years 16.66 26.31 0.8 0.8 15 20 11.5 36.36
36–45 years 16.66 0 15.04 15.04 60 20 30.76 22.72
>45 years 8.33 0 54.14 84.14 20 60 57.69 40.90
Family history (% patients)
Present 35.48 57.07 52 70.81
Absent 65.42 42.93 48 29.17
Basal metabolic index (BMI, % patients)
Underweight (U) 38.6 1.76 12 5
Healthy (H) 58 25.5 76 55
Overweight (H) 3.2 47.3 12 35
Obese (O) 0 22.9 0 5
Very obese (VOb) 0 2.27 0 0
Mean BMI 19.96 ± 0.629 27.95 ± 0.26 22 ± 0.55 25.68 ± 0.65
BMI range 13.75–25 16–45 15–26 16.5–34
Treatment regimen (% patients)
Insulin 92.5 3.5 20 12
OHA 3.5 65.5 16 53.5
Insulin + OHA 3.5 29.5 60 34.5
Drug therapy (% patients)
1 DT 96.4 18 23.6 28
2 DT 3.6 28 23.8 28
3 DT 0 29 23.8 12.5
4 DT 0 21.5 28.5 22
5D T 0 3 0 9 . 4
Mean HbA1c levels (%) 9.661 ± 1.10 8.21 ± 0.25 10.45 ± 0.75 7.89 ± 0.47
Mean cholesterol levels (mg/dL) No data available 181.96 ± 5.28 222.33 ± 26.87 210.90 ± 13.59
Mean C-peptide levels (ng/mL) 0.36 ± 0.05 1.26 ± 0.36 0.34 ± 0.05 0.63 ± 0.15
GAD autoantibodies 0.76 ± 0.05 0.7 ± 0.06 0.95 ± 0.06 1.01 ± 0.07
(units/mL) Absent Absent Present Present
3. Results andDiscussion
Results of diﬀerent parameters evaluated amongst diﬀerent
classes of diabetic patients are summarized in Table 1.
According to reports, type 2 diabetes constitutes a major
section, that is, 80–90% of the total diabetic population
[3]. Furthermore, about 20% of the patients diagnosed with
LADA may have type 2 diabetes. This accounts for 5–10%
of the total diabetes population, the same number as type
1d i a b e t e s[9]. The results of the present study in a diabetic
population revealed that the prevalence of type2diabeteswas
the highest (79.2%), followed by type 1 diabetes (6.2%) and
LADA(5%)beingnearlyequal.Thisimpliesthattheﬁndings
are in accordance with the reported data. Another group,
comprisingofpatientswhocouldnotbecategorizedintoone
particular class of diabetes constituted of around 10% of the
total diabetic population.
The prevalence of diabetes among males and females
varies with geographical location, ethnicity, genetic and
environmental factors (Figure 1).4 ISRN Pharmacology
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Figure 1: Prevalence of diﬀerent types of diabetes in males and fe-
males. Black circle: prevalence pattern signiﬁcantly diﬀerent in type
1 diabetes as compared to type 2 diabetes (P<0.01). Black square:
prevalence pattern signiﬁcantly diﬀerent in LADA as compared to
type 1 diabetes (P<0.01).
According to the global prevalence of diabetes studies,
overall, diabetes prevalence is higher in men than in women
[15]. The results of the present study revealed that diabetes
was found to be more prevalent in men (61%) than in
women (39%). Thus the ﬁndings are in accordance with the
reported data [15, 16]. Further studies on prevalence of dif-
ferent types of diabetes in males and females revealed that
there was a signiﬁcant diﬀerence in the prevalence pattern of
diabetes in males and females in LADA and t y p e1d i a b e t e s
(P<0.01). Type 1 diabetes was found to be more prevalent in
females (61.3%) than in males (38.7%), whereas the preva-
lence of LADA was signiﬁcantly more in males (80%) than
in females (20%). This suggests that males might be more
prone towards development of LADA than females. There
was a signiﬁcant diﬀerence in prevalence pattern of type 1
and type 2 diabetes (P<0.01). The prevalence pattern of type
2d i a b e t e s , LADA, and undiagnosed patients was similar with
no signiﬁcant diﬀerences. Amongst type 2 diabetes patients,
62.12% were males and 37.87% were females. The similar
prevalence pattern was seen in undiagnosed patients, that
is, 54.16% males and 45.83% females suggesting that these
patients are likely to be type 2 or LADA.
Studies showed that the average age in diﬀerent diabetic
populations varied signiﬁcantly. The average age of LADA
(40.88 ± 1.48 years) patients was found to be signiﬁcantly
lower than type2diabetesand signiﬁcantly higher than type1
diabetes (P<0.01). The average age of patients of type 1 dia-
betes (21.64 ±1.97 years) was found to be signiﬁcantly lower
than type 2 and LADA (P<0.01). The average age of pa-
tientswithtype2diabetes(55.69±0.47years)wasthehighest
as compared to previous two groups. The average age in
undiagnosed patients (44.46 ± 1.56 years) suggested that
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Figure 2: Average age at onset of diﬀerent types of diabetes. Black
circle: signiﬁcantly lower age of onset in type 1 diabetes compared to
type 2 diabetes (P<0.001) and undiagnosed patients (P<0.001).
Black square: signiﬁcantly higher age of onset in type 2 diabetes
compared to undiagnosed patients (P<0.001). Black triangle:
signiﬁcantlylowerageofonsetinLADAcomparedtotype2diabetes
(P<0.001) and higher than Type 1 (P<0.001).
these patients are more likely to be patients with LADA than
that with type 2 diabetes.
The average age at onset is a very critical factor in deter-
mining the type of diabetes as well as the treatment regimen
to be decided for the patient. According to reported data,
one of the important identifying characteristics of LADA is
adultageatonset(>25years)[6].Thepresentstudiesshowed
that the average age at onset of diabetes in patients with
LADA (33.4 ± 2.15 years) was signiﬁcantly higher than pa-
tients with t y p e1d i a b e t e spatients (12.55 ± 1.34 years) (P<
0.001) and signiﬁcantly lower than patients with type 2 dia-
betes (48.01±0.50 years) (P<0.001). The mean age at onset
in undiagnosed patients was observed to follow the same
pattern (37.68 ± 1.28 years) strongly suggesting that these
patients are more likely to be patients of LADA than type 2
diabetes. Results are presented in Figure 2.
Further studies regarding the prevalence of diabetes in
diﬀerent age groups revealed that type 1 diabetes was found
to be most frequently occurring in the age group of 12–24
years in both males and females. Similarly t y p e2d i a b e t e swas
found to be most prevalent in males and females above 45
years of age. Interestingly LADA was found to occur most
frequently in males of 36–45 years of age, while it was seen to
aﬀect most females above 45 years of age. This ﬁnding may
lead to an assumption that LADA might be aﬀecting females
at a higher age than males.
Theimpactoffamilyhistoryofdiabetes(FHD)onLADA
is less well understood than those for type 1 and type 2 dia-
betes [17]. Studies indicate that LADA has the same genetic
features characteristic of type 1 diabetes, including an
increased frequency of HLADQB1 genotypes [18, 19]. On
the other hand, results from a British study indicated that
33%ofpatientswithLADAhaverelativeswithtype2diabetes
[20]. These ﬁndings suggest that LADA may share inherited
features with both type 1 and type 2 diabetes [11]. Results
of family history in diﬀerent types of diabetes revealed
signiﬁcant diﬀerences in the family history pattern of LADAISRN Pharmacology 5
Figure 3: Family history pattern in LADA. F-Father, M-Mother,
MF-Mother and Father, B/S- Brother or Sister.
and type 1 diabetes (P<0.05). While family history was
absent in majority of patients with type 1 (65.42%), type 2
(57%), LADA (52%) as well as undiagnosed patients (70%)
showed signiﬁcant presence of family history. The pattern
seen in undiagnosed patients was signiﬁcantly diﬀerent than
in t y p e1d i a b e t e s(P<0.01). There was a signiﬁcant dif-
ference in family history patterns of type1and type2diabetes
(P<0.01). Absence of family history in patients with type
1 suggests that β-cell destruction in type 1 diabetes might
be due to viral infections or triggered autoimmune mecha-
nisms.Thenoticeablepresenceoffamilyhistoryintype2dia-
betes is in accordance with the fact that type 2 diabetes is
stronglyhereditaryinnature.AmongLADApatients,asigni-
ﬁcant population (32%) showed paternal inheritance while a
small proportion (8%) showed maternal inheritance, sibling
inheritance(8%)and4%showedbothpaternalandmaternal
inheritance. The results are shown in Figure 3.
Some reports suggest that LADA patients are unlikely to
have a family history of t y p e2d i a b e t e s[10], while some indi-
cate presence of family history as an important risk factor for
the development of LADA [11]. The interesting observation
obtainedinthepresentstudywouldpossiblyopennewdoors
for future exploration regarding pattern of inheritance in
LADA patients.
In an eﬀort to correlate BMI values with the type of dia-
betes, it was observed that a majority of patients with type
1d i a b e t e swere healthy (58%) or underweight (38.6%) in
nature suggesting possible alteration of carbohydrate, lipid,
and protein metabolisms due to absolute insulin deﬁciency
(Figure 4). The BMI values of patients with type 1 diabetes
(19.96 ± 0.629) were signiﬁcantly lower than patients with
type 2 diabetes (27.95 ± 0.26) (P<0.001). BMI values of pa-
tients with type 2 diabetes showed that most of the patients
of this category were overweight (47.3%). Signiﬁcant pro-
portions of these patients were found to be obese (22.9%)
and very obese (2.27%). This implies that the ﬁndings are
in agreement with the existing literature which states that
obesity is one of the prime factors leading to development of
t y p e2d i a b e t e sand insulin resistance [21]. Furthermore, the
BMI values of LADA patients (22 ± 0.55) were signiﬁcantly
lower than patients with type 2 diabetes (P<0.001)
conﬁrming the nonobese nature of these patients. None of
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Figure 4:BMIvaluesindiﬀerenttypesofdiabetes.U-Underweight,
H-Healthy, O-Overweight, Ob-Obese, Vob-Very Obese.
the patients were obese which rules out the involvement of
obesityandinsulinresistanceindevelopmentofLADA.Most
of the patients (76%) displayed BMI values corresponding
to healthy individuals suggesting that the gradual β-cell des-
truction in LADA is insuﬃcient to cause signiﬁcant weight
loss. Reports suggest that BMI values are lower in LADA
patients compared to patients with type 2 diabetes [22]. Thus
our ﬁndings were in accordance with the reported data. The
mean BMI levels in undiagnosed patients (25.68 ± 0.65)
were signiﬁcantly lower than patients with t y p e2d i a b e t e s
(P<0.05) and higher than patients with type 1 diabetes (P<
0.001). A majority of the undiagnosed patients (55%) were
foundtobehealthy,whileanoticeableproportion(35%)was
foundtobeoverweight,thoughtheproportionofoverweight
patients (35%) was relatively less in undiagnosed patients
than that of type 2 diabetics (47.3%) suggesting that these
patients are likely to be patients of LADA.
Studiesrelatedtothetreatmentregimenforpatientswith
diﬀerent types of diabetes revealed that almost all (92.5%)
patients with type 1 diabetes maintained optimum BSL with
insulin. Majority of patients with type 2 diabetes (65.5%)
were treated with oral hypoglycemic agents (OHA) while
a noticeable proportion (29.5%) was on a combination of
insulin and OHA suggesting development of progressive in-
sulin dependence due to impairment in insulin secretion by
various mechanisms [21, 23]. Figure 5 depicts the results of
statisticalanalysisontreatmentregimenfordiﬀerentdiabetic
patients.
One of the major characteristics of LADA patients is
initial response to OHA treatment [6]. Insulin dependency
develops within a few years with gradual β-cell destruction
necessitating a combined therapeutic regimen. In agreement
with the reported literature, a major proportion of LADA
patients (60%) were found to be taking a combination of
insulin and OHA. The observation would help in designing
an eﬀective therapeutic regimen for LADA patients, that is, a
combined treatment should be prescribed at the time of dia-
gnosisofLADAtopreservetheremainingβ-cellmassthough
it is still unclear whether early treatment with insulin is
beneﬁcial for the remaining β-cells [9]. Additionally, an
initial response to OHA with gradual insulin dependency6 ISRN Pharmacology
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Figure 5: Treatment regimen for diﬀerent types of diabetes. I-
Insulins, OHA-Oral Hypoglycemic Agents.
observed in patients younger than the usual age occurrence
of type 2 diabetes would be a strong identifying character-
istic for LADA patients. Thus the type of treatment that
patients comply to, the most, can be predictive in diﬀerent
types of diabetes, speciﬁcally, LADA. A majority of the
undiagnosed patients (53.5%) were found to be on OHA,
while a noticeable proportion (34.5%) was found to be on
a combined treatment. The proportion of patients under
combined treatment (34.5%) was relatively more than that
of patients with type 2 diabetes (29.5%) on a combined
treatment. The numbers of undiagnosed patients on OHA
alone were less than that with type 2 diabetes, while the
number of patients on insulin and OHA was more than that
with type 2 diabetes. This strongly suggests that these are
likely to be LADA patients who initially respond to OHA,
but insulin dependency may occur within some time and the
numberofpatientsonacombinedtreatmentmayincreasein
near future.
Furthermore, a detailed study about the drug therapy
distribution in diﬀerent types of diabetic patients was per-
formed and patients were evaluated for the type of therapy
beinggiven,thatis,monodrugtherapyormultidrugtherapy.
Almost all patients with type1diabetes(96.4%) showed opti-
mumBSLwithexclusiveinsulinmonotherapy.Noclearindi-
cation was observed for the remaining types of diabetes indi-
cating that optimum BSL were maintained by a multidrug
therapy (insulin + OHA or a combination of various OHA).
The HbA1c levels determination in diabetes gives an idea
about the glycemic control during the last three months.
Generallyvaluesabovenormalvalues(5–7%)indicateapoor
glycemic control [24]. HbA1c levels determined in patients
with diﬀerent types of diabetes showed that LADA patients
(10-11%) had signiﬁcantly higher levels compared to type 1
(9-10%) and type2diabetes(8–8.5%) (P<0.05). This was in
agreement with the published data [23]. This shows poorer
glycemic control in LADA patients compared to type 1 and
t y p e2d i a b e t e s . Patients with t y p e1d i a b e t e sshowed relatively
highervaluesascomparedtopatientswithtype2diabetesand
lowerthanthatofpatientswithLADA.Undiagnosedpatients
showed HbA1c values (7-8%) similar to patients with type 2
diabetes. The values were higher than normal HbA1c levels
(5–7%) in all patients, indicating poor glycemic control in
all patients [24].
Determination of serum cholesterol levels revealed that
LADA patients (200–250mg/dL) had signiﬁcantly higher
cholesterol levels than patients with type 2 diabetes (180–
190mg/dL), which was found to be in accordance with
existing data [4]. This indicates that LADA patients are at
a higher risk of developing cardiovascular complications
than patients with type 2 diabetes. No data was available
for patients with type 1 diabetes. Interestingly, undiagnosed
patients also displayed cholesterol values greater than that of
patients with type 2 diabetes suggesting possible categoriza-
tion of these patients as LADA patients.
C-peptide is secreted at equimolar concentrations with
insulin and is not degraded as rapidly as insulin. Hence
determination of C-peptide is an advantageous test to quan-
tify insulin and therefore to evaluate β-cell function. Since
LADA is an autoimmune type of diabetes characterized by
progressive β-cell destruction, estimation of C-peptide levels
would prove to be an important measure to evaluate insulin
secretion and β-cell function. The results of the C-peptide
determination showed signiﬁcantly low levels of C-peptide
in LADA patients (0.34 ± 0.05ng/mL) compared to patients
withtype2diabetes(1.26ng/mL) (P<0.0 5 ) .T h i si si na c c o r -
dance with existing data [6]. Many other studies suggested
that LADA (also known as Ab positive type 2 diabetes)h a s
lower C-peptide levels than patients with Ab negative type 2
diabetes [25–27]. Patients with t y p e1d i a b e t e salso displayed
lower C-peptide values (0.36 ± 0.05ng/mL) as compared to
patients with type 2 diabetes. Low C-peptide values in both
the cases suggest insulin deﬁciency due to autoimmune β-
celldestruction.Patientswithtype2diabetesdisplayedhigher
C-peptide values (1.26 ± 0.36ng/mL) which show hyperin-
sulinemia due to compensatory increase in insulin secretion
due to insulin resistance in type 2 diabetes.C - p e p t i d ev a l u e s
of undiagnosed patients were found to be higher than that of
patients with type 1 and LADA, but noticeably lower than
that of patients with type 2 diabetes (0.63 ± 0.15ng/mL)
suggesting that insulin deﬁciency could progress with time
and lower C-peptiode values may be achieved at a later stage.
This indicates that these patients are likely to be patients of
LADA. Results are presented in Figure 6.
The immunological evidence, common in both type 1
diabetes and LADA, is demonstrated by the presence of
autoantibodies against islet cell antigens in the patients’
sera.Speciﬁcally,theseantigensinclude65kDaglutamicacid
decarboxylase (GAD65) and insulinoma-associated antigen
(IA2). While type 1 diabetes shows both these autoanti-
bodies, LADA typically demonstrates production of GAD65
autoantibodies [14]. Hence estimation of GAD autoanti-
bodies can be used as an important diagnostic marker for
diagnosis of LADA. Since the test was qualitative in nature,
GAD autoantibodies levels above 0.95 units/mL indicated
presence of GAD autoantibodies, while levels below this
indicated absence of autoantibodies. Results of GAD autoan-
tibodies determination revealed marked presence of GADISRN Pharmacology 7
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Figure 6:MeanC-peptidelevelsindiﬀerenttypesofdiabetes.Black
circle: signiﬁcantly lower C-peptide levels in type 1 diabetes as com-
paredtotype2diabetes(P<0.05).Blacksquare:signiﬁcantlyhigher
C-peptide levels in type 2 diabetes as compared to type 1 diabetes
and LADA (P<0.05). Black triangle: signiﬁcantly lower C-peptide
levels in LADA as compared to type 2 diabetes (P<0.05).
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Figure 7: Mean GAD autoantibodies levels in diﬀerent types of
diabetes. Black square: signiﬁcantly lower GAD autoantibodies
levels in type 2 diabetes as compared to type 1 diabetes, LADA, and
undiagnosed patients (P<0.05). Black circle: signiﬁcantly higher
GAD autoantibodies levels in LADA as compared to type 1 diabetes
and type 2 diabetes (P<0.05). Black triangle: signiﬁcantly higher
GAD autoantibodies levels in undiagnosed patients as compared to
type 1 diabetes (P<0.01) and type 2 diabetes (P<0.05). (+) in-
dicates presence of GAD auto antibodies. (−) indicates absence of
GAD auto antibodies.
autoantibodies predominantly in LADA patients (0.95 ±
0.06units/mL) as compared to patients with type 2 diabetes
(P<0.05) (Figure 7).
GAD autoantibodies were signiﬁcantly present in undi-
agnosed patients (1.01 ± 0.07 units/mL) as compared to
patients with type 2 diabetes (0.7±0.06 units/mL) and type 1
diabetes(0.76±0.05units/mL).Thisstronglydepictsautoim-
mune nature of the disease, especially LADA, which is signif-
icantly in accordance with the existing data [6]. The charac-
teristic presence of these antibodies in undiagnosed patients
further strengthens the fact that these patients are most likely
to be patients of LADA. The absence of GAD autoantibodies
in type 2 diabetes implicates nonautoimmune nature of the
disease[28,29].Theabsenceoftheseautoantibodiesintype1
diabetes do not imply that the disease is nonautoimmu-
ne in nature, but merely suggests that other autoantibodies
like ICA, IA2, or tyrosine phosphatase autoantibodies may
be involved [30, 31].
4. Conclusions
LADApatientscompriseanimportantsectionofthediabetic
population, its prevalence being nearly equal as that of type
1d i a b e t e s . It can be characterized predominantly by adult
age at onset (30–40 years), nonobese body type, and initial
response to OHA gradually leading to insulin dependency,
characteristically low C-peptide levels, and marked presence
of GAD autoantibodies. Thus determination of C-peptide
levels and GAD autoantibodies is strongly recommended for
conﬁrmatorydiagnosis ofLADA.Thecharacteristicpresence
of GAD autoantibodies in LADA implies that further studies
that identify possible role of GAD autoantibodies in LADA
may help in understanding the pathogenesis of the disease.
Interestingly the study showed that LADA seems to aﬀect
males more than females. LADA patients have also shown
signiﬁcant presence of family history, further exploration of
which would provide newer insights into the role of family
history as an important risk factor in development of LADA.
Furthermore, genotyping of LADA patients will prove to
be substantial in understanding the role of various genes
involved in the disease. In conclusion, it appears that, while
some anthropologic characteristics can be useful for the
preliminary screening of LADA patients in a diabetic popu-
lation, C-peptide levels and GAD autoantibodies determina-
tion can be considered as conﬁrmatory diagnostic markers
for LADA. Appropriate diagnosis of LADA would prevent
misdiagnosis as type 2 diabetes and would help in optimum
treatment of LADA patients so that residual β-cell function
is preserved and the further autoimmune destruction of β-
cells is delayed. For further information, see Supplementary
Material available online at doi:10.5402/2012/580202.
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